Verastem, INC. (VSTM) — SEC Filings

Overview

Verastem, INC. (VSTM) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 31, 2025: Verastem, Inc. filed an 8-K on December 31, 2025, reporting events that occurred on December 29, 2025. The filing indicates it is for Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. The company is incorporated in Delaware and its principal executive offices are located

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 2 bearish, 48 neutral. The dominant filing sentiment for Verastem, INC. is neutral.

Filing Type Overview

Verastem, INC. (VSTM) has filed 25 8-K, 5 10-Q, 2 DEF 14A, 2 10-K, 12 SC 13G/A, 4 SC 13G with the SEC between Jan 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (50)

• Verastem, Inc. Files 8-K for Regulatory, Other Events — 8-K · Dec 31, 2025 Risk: low
  Verastem, Inc. filed an 8-K on December 31, 2025, reporting events that occurred on December 29, 2025. The filing indicates it is for Regulation FD Disclosure,
• Verastem, Inc. Files 8-K on Officer/Director Changes — 8-K · Dec 19, 2025 Risk: medium
  Verastem, Inc. filed an 8-K on December 19, 2025, reporting events as of December 15, 2025. The filing covers the departure of directors or certain officers, el
• Verastem, Inc. Files 8-K Report — 8-K · Nov 17, 2025 Risk: low
  On November 13, 2025, Verastem, Inc. filed an 8-K report. The filing indicates "Other Events" and "Financial Statements and Exhibits" as key items. The company
• 8-K Filing — 8-K · Nov 4, 2025
• Verastem, Inc. Files 8-K Report — 8-K · Oct 23, 2025 Risk: low
  On October 23, 2025, Verastem, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regulati
• Verastem, Inc. Files 8-K Report — 8-K · Oct 20, 2025 Risk: low
  On October 19, 2025, Verastem, Inc. filed an 8-K report. The filing indicates that the company is providing information related to Regulation FD disclosure, oth
• Verastem, Inc. Files 8-K for Regulation FD Disclosure — 8-K · Sep 8, 2025 Risk: low
  Verastem, Inc. filed an 8-K on September 8, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the company's p
• Verastem, Inc. Files 8-K Report — 8-K · Aug 13, 2025 Risk: low
  On August 13, 2025, Verastem, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regulatio
• Verastem Reports Continued Losses Amidst R&D Focus — 10-Q · Aug 7, 2025 Risk: high
  Verastem, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with the prior year periods, as the company is still in the clin
• Verastem, Inc. Files 8-K Report — 8-K · Jun 2, 2025 Risk: low
  On June 2, 2025, Verastem, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regulation F
• Verastem, Inc. Files 8-K for Shareholder Vote — 8-K · May 23, 2025 Risk: low
  On May 22, 2025, Verastem, Inc. filed an 8-K report detailing a shareholder meeting where proposals were submitted for a vote. The filing also included informat
• Verastem, Inc. Files Q1 2025 10-Q — 10-Q · May 13, 2025 Risk: medium
  Verastem, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial performance and business activities, including details
• Verastem, Inc. Files 8-K Report — 8-K · May 8, 2025 Risk: low
  On May 8, 2025, Verastem, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and other events, along with financial statements an
• Verastem, Inc. Files 8-K: Material Agreement & Equity Sales — 8-K · Apr 25, 2025 Risk: medium
  On April 25, 2025, Verastem, Inc. filed an 8-K report detailing a material definitive agreement. The filing also covers unregistered sales of equity securities
• Verastem Files DEF 14A, Details Executive Compensation — DEF 14A · Apr 8, 2025 Risk: medium
  Verastem, Inc. filed its DEF 14A on April 8, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation and related party tra
• Verastem, Inc. Files 8-K Report — 8-K · Mar 20, 2025 Risk: low
  On March 20, 2025, Verastem, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and the inclusion of Financial Statements and Exhi
• Verastem, Inc. Files 2024 Annual Report — 10-K · Mar 20, 2025 Risk: medium
  Verastem, Inc. filed its 10-K for the fiscal year ending December 31, 2024. The company, incorporated in Delaware, is in the pharmaceutical preparations industr
• Verastem, Inc. Files 8-K: Regulation FD Disclosure & Other Events — 8-K · Jan 23, 2025 Risk: low
  On January 14, 2025, Verastem, Inc. filed an 8-K report detailing a Regulation FD Disclosure and Other Events. The filing also includes Financial Statements and
• Verastem, Inc. Files 8-K: Officer/Director Changes & Financials — 8-K · Jan 21, 2025 Risk: medium
  Verastem, Inc. filed an 8-K on January 21, 2025, reporting events as of January 14, 2025. The filing covers the departure of directors or certain officers, elec
• Verastem, Inc. Files 8-K with Key Agreements and Financial Updates — 8-K · Jan 13, 2025 Risk: medium
  On January 13, 2025, Verastem, Inc. filed an 8-K report detailing several significant events. These include entering into and terminating material definitive ag
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G Filing — SC 13G · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 13, 2024
• SC 13G/A Filing — SC 13G/A · Nov 12, 2024
• SC 13G Filing — SC 13G · Nov 8, 2024
• Verastem, Inc. 10-Q: Assets $25.3M, Liabilities $40.3M — 10-Q · Nov 6, 2024 Risk: high
  Verastem, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported total assets of $25.281 million and total liabilities of $40.262 mi
• SC 13G Filing — SC 13G · Oct 24, 2024
• Verastem, Inc. Files 8-K Report — 8-K · Oct 17, 2024 Risk: low
  On October 17, 2024, Verastem, Inc. filed an 8-K report detailing several key events. The filing includes information on Regulation FD disclosures, other events
• Verastem, Inc. Files 10-Q for Q2 2024 — 10-Q · Aug 8, 2024 Risk: medium
  Verastem, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported significant research and development expenses, with specific figures not
• SC 13G Filing — SC 13G · Jul 29, 2024
• Verastem, Inc. Files 8-K Report — 8-K · Jul 25, 2024 Risk: low
  On July 23, 2024, Verastem, Inc. filed an 8-K report detailing an "Other Event" and "Financial Statements and Exhibits." The filing does not disclose specific f
• Verastem, Inc. Files 8-K: Other Events Noted — 8-K · Jul 23, 2024 Risk: medium
  On July 23, 2024, Verastem, Inc. filed an 8-K report. The filing indicates an "Other Events" item, suggesting a significant development not covered by other sta
• Verastem, Inc. Files 8-K Report — 8-K · Jun 26, 2024 Risk: low
  On June 26, 2024, Verastem, Inc. (VSTM) filed an 8-K report. The filing indicates that the company's common stock is traded on The Nasdaq Capital Market under t
• Verastem, Inc. Files 8-K Report — 8-K · May 24, 2024 Risk: low
  On May 24, 2024, Verastem, Inc. (VSTM) filed an 8-K report. The filing indicates the company's principal executive offices are located at 117 Kendrick Street, S
• Verastem, Inc. Files 8-K with Shareholder Votes and Disclosures — 8-K · May 23, 2024 Risk: low
  On May 23, 2024, Verastem, Inc. filed an 8-K report detailing several key events. The company announced the submission of matters to a vote of its security hold
• Verastem, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 9, 2024 Risk: low
  Verastem, Inc. (VSTM) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Verastem, Inc. filed a 10-Q report for the period ending March 31, 2024. The
• Verastem, Inc. Announces 2024 Annual Meeting of Stockholders on May 23 — DEF 14A · Apr 12, 2024 Risk: low
  Verastem, Inc. (VSTM) filed a Proxy Statement (DEF 14A) with the SEC on April 12, 2024. The 2024 Annual Meeting of Stockholders for Verastem, Inc. will be held
• Verastem, Inc. Files 8-K Report — 8-K · Apr 9, 2024 Risk: low
  On April 9, 2024, Verastem, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specific
• Verastem, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 14, 2024 Risk: medium
  Verastem, Inc. (VSTM) filed a Annual Report (10-K) with the SEC on March 14, 2024. Verastem, Inc. filed its 2023 Form 10-K on March 14, 2024. The company's fisc
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• Soleus Capital Amends Verastem Stake, Updates 13G Filing — SC 13G/A · Feb 2, 2024
  Soleus Capital Master Fund, L.P. filed an amendment to their Schedule 13G, indicating a change in their beneficial ownership of Verastem, Inc. common stock as o
• Verastem Files Routine 8-K, Confirms Nasdaq Listing — 8-K · Jan 29, 2024
  Verastem, Inc. filed an 8-K on January 29, 2024, primarily to disclose general corporate information and confirm its status as a publicly traded company on The
• Verastem Files 8-K on Shareholder Vote Submission — 8-K · Jan 19, 2024
  Verastem, Inc. filed an 8-K on January 17, 2024, to report the submission of matters to a vote of security holders. This filing indicates that the company held

Risk Profile

Risk Assessment: Of VSTM's 31 recent filings, 2 were flagged as high-risk, 10 as medium-risk, and 19 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Verastem, INC.'s most recent 10-Q filing (Aug 7, 2025):

• Revenue: $0
• Net Income: -$29.5M
• EPS: N/A
• Debt-to-Equity: N/A
• Cash Position: N/A
• Operating Margin: N/A
• Total Assets: N/A
• Total Debt: N/A

Key Executives

• Mr. Daniel Paterson
• Mr. Brian Stuglik
• Paul Bunn
• Anil Kapur
• Daniel Paterson
• Michelle Robertson

Industry Context

Verastem operates in the highly competitive pharmaceutical industry, specifically within the oncology sector. The market for treatments for non-small cell lung cancer and low-grade serous ovarian cancer is dynamic, with ongoing innovation and the presence of both large pharmaceutical companies and smaller biotech firms. Success is heavily dependent on the efficacy and safety of drug candidates, navigating complex regulatory pathways, and securing market access.

Top Tags

financials (12) · 8-K (9) · disclosure (7) · corporate-governance (6) · filing (5) · 8-k (5) · regulatory-filing (4) · sec-filing (3) · 10-Q (3) · regulation-fd (2)

Key Numbers

• Commission File Number: 001-35403 — Identifies the company's filing with the SEC.
• IRS Employer Identification No.: 27-3269467 — Tax identification number for the company.
• Revenue: $0 — No revenue reported for Q2 2025 or H1 2025, indicating pre-commercial stage.
• Net Loss (Q2 2025): -$29.5M — Increased from -$29.1M in Q2 2024, reflecting ongoing operational costs.
• Net Loss (H1 2025): -$59.2M — Increased from -$58.1M in H1 2024, demonstrating consistent cash burn.
• R&D Expenses (Q2 2025): $22.3M — Significant investment in clinical trials for VS-6766.
• R&D Expenses (H1 2025): $44.8M — Primary driver of operating expenses, crucial for product development.
• Reporting Period End Date: 20250331 — Indicates the end of the financial quarter being reported.
• Filing Date: 20250513 — The date the 10-Q was officially submitted to the SEC.
• Deferred Revenue: $1.2M — Represents revenue recognized in advance, impacting future revenue streams.
• Grants Receivable Net: $44.78M — Indicates funds expected from grants, a potential source of income.
• Deferred Revenue Current: $25.28M — Short-term portion of deferred revenue, relevant for near-term cash flow.
• ZIP Code: 02494 — Part of the principal executive office address.
• Total Assets: $25.281M — As of September 30, 2024
• Total Liabilities: $40.262M — As of September 30, 2024

Related Companies

VERA

Frequently Asked Questions